Statement: The least common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 1, 3D and 3C.
Primary_evidence: Outcome Measurement:    Pathological Tumor Response to Neoadjuvant Chemotherapy (Taxotere and AC)   The patients' pathological response were assessed using Chevalier's system which graded the responses into Chevalier 1, 2, 3A, 3B, 3C, 3D, and 4, defined as:   Disappearance of all tumor either on macroscopic or microscopic assessment in both the breast and LN (pCR)   Presence of in situ carcinoma in the breast. No invasive tumor in breast and no tumor in LN (pCR)   Presence of invasive cancer with stromal alteration such as sclerosis or fibrosis (pPR) 3A: Subjectively > 75% therapeutic effect 3B: Subjectively between 50% - 75% therapeutic effect 3C: Subjectively between 25% - 50% therapeutic effect 3D: Subjectively < 25% therapeutic effect OR Grade 4   No or few modification of tumoral appearance (pNR).   Time frame: 10 years Results 1:    Arm/Group Title: A: Taxotere/Docetaxel   Arm/Group Description: Chemotherapy In Arm A, patients will receive single agent Taxotere (100 mg/m2) every 3 weeks for 4 cycles before surgery. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. This will be followed by standard adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles. For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. This is done in order to minimize Adriamycin-induced cardiotoxicity. Taxotere/Docetaxel: Taxotere   doxorubicin: AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.   Overall Number of Participants Analyzed: 83   Measure Type: Number   Unit of Measure: participants  1: 3   2: 2   3A: 18   3B: 15   3C: 18   3D: 10 4: 3 N/A: 14 Results 2:    Arm/Group Title: B: AC Adriamycin/Cytoxan   Arm/Group Description: In Arm B, patients will receive AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery. For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. This will be followed by 4 cycles of single agent Taxotere (100 mg/m2) every 3 weeks. Adriamycin/Cytoxan: Adriamycin/Cytoxan   Overall Number of Participants Analyzed: 84   Measure Type: Number   Unit of Measure: participants  1: 9   2: 1   3A: 15   3B: 18   3C: 15   3D: 8 4: 0 N/A: 18